Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 1 · 33.3%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Withdrawals due to adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

1 finding from 1 review

Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.51 [0.81, 2.8]
1 study · 860 participants
Moderate

Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis

It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.42 [0.89, 2.25]
2 studies · 1556 participants
Very low